Evaluation of the Epidemiologic Utility of Secondary Typing Methods for Differentiation of Mycobacterium tuberculosis Isolates A Kwara, R Schiro, LS Cowan, NE Hyslop, MF Wiser, S Roahen Harrison, ... Journal of Clinical Microbiology 41 (6), 2683-2685, 2003 | 176 | 2003 |
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients A Kwara, M Lartey, KWC Sagoe, E Kenu Aids 23 (16), 2101-2106, 2009 | 167 | 2009 |
CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV‐infected patients A Kwara, M Lartey, KW Sagoe, NL Rzek, MH Court British journal of clinical pharmacology 67 (4), 427-436, 2009 | 152 | 2009 |
Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status A Kwara, TP Flanigan, EJ Carter The International Journal of Tuberculosis and Lung Disease 9 (3), 248-257, 2005 | 143 | 2005 |
Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy A Kwara, A DeLong, N Rezk, J Hogan, H Burtwell, S Chapman, ... Clinical infectious diseases 46 (5), 719-725, 2008 | 102 | 2008 |
Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island A Kwara, JS Herold, JT Machan, EJ Carter Chest 133 (4), 862-868, 2008 | 95 | 2008 |
Meningitis caused by a serogroup W135 clone of the ET‐37 complex of Neisseria meningitidis in West Africa A Kwara, RA Adegbola, PT Corrah, M Weber, M Achtman, G Morelli, ... Tropical Medicine & International Health 3 (9), 742-746, 1998 | 82 | 1998 |
Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz ML Carten, JJ Kiser, A Kwara, S Mawhinney, S Cu-Uvin Infectious diseases in obstetrics and gynecology 2012, 2012 | 73 | 2012 |
Pharmacokinetics of Efavirenz When Co‐administered With Rifampin in TB/HIV Co‐infected Patients: Pharmacogenetic Effect of CYP2B6 Variation A Kwara, M Lartey, KW Sagoe, F Xexemeku, E Kenu, J Oliver‐Commey, ... The Journal of Clinical Pharmacology 48 (9), 1032-1040, 2008 | 67 | 2008 |
A systematic review on the effect of HIV infection on the pharmacokinetics of first-line tuberculosis drugs A Daskapan, LR Idrus, MJ Postma, B Wilffert, JGW Kosterink, Y Stienstra, ... Clinical pharmacokinetics 58, 747-766, 2019 | 65 | 2019 |
Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy AN Brown, GL Drusano, JR Adams, JL Rodriquez, K Jambunathan, ... MBio 6 (6), 10.1128/mbio. 01741-15, 2015 | 62 | 2015 |
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes DW Haas, A Kwara, DM Richardson, P Baker, I Papageorgiou, EP Acosta, ... Journal of Antimicrobial Chemotherapy 69 (8), 2175-2182, 2014 | 61 | 2014 |
Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy A Kwara, M Lartey, KW Sagoe Aids 25 (3), 388-390, 2011 | 59 | 2011 |
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all A Kwara, G Ramachandran, S Swaminathan Expert opinion on drug metabolism & toxicology 6 (1), 55-68, 2010 | 59 | 2010 |
Respiratory illness after severe respiratory syncytial virus disease in infancy in The Gambia MW Weber, P Milligan, B Giadom, MA Pate, A Kwara, AD Sadiq, ... The Journal of pediatrics 135 (6), 683-688, 1999 | 56 | 1999 |
The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance F Gehre, J Otu, L Kendall, A Forson, A Kwara, S Kudzawu, AO Kehinde, ... BMC medicine 14, 1-12, 2016 | 54 | 2016 |
Factors associated with mortality and default among patients with tuberculosis attending a teaching hospital clinic in Accra, Ghana NT Burton, A Forson, MN Lurie, S Kudzawu, E Kwarteng, A Kwara Transactions of the Royal Society of Tropical Medicine and Hygiene 105 (12 …, 2011 | 53 | 2011 |
Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV‐Coinfected Ghanaian Patients: UGT2B7*1c Is … A Kwara, M Lartey, I Boamah, NL Rezk, J Oliver‐Commey, E Kenu, ... The Journal of Clinical Pharmacology 49 (9), 1079-1090, 2009 | 53 | 2009 |
Pharmacokinetics of first-line antituberculosis drugs using WHO revised dosage in children with tuberculosis with and without HIV coinfection A Kwara, A Enimil, FS Gillani, H Yang, AM Sarfo, A Dompreh, A Ortsin, ... Journal of the Pediatric Infectious Diseases Society 5 (4), 356-365, 2016 | 50 | 2016 |
Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies L Cao, A Kwara, DJ Greenblatt Journal of Pharmacy and Pharmacology 69 (12), 1762-1772, 2017 | 47 | 2017 |